All News

For millennia, humans have linked feces and disease, making the connection that since it’s gross, it’s probably also harmful.

Best practices for prescribing an immunomodulatory-based therapy or a proteasome inhibitor as treatment for relapsed/refractory multiple myeloma.

Considerations for treating patients with relapsed/refractory multiple myeloma with elotuzumab, daratumumab, or isatuximab based on more recent clinical trial data and differences between each treatment option.

Variables considered by healthcare professionals when selecting an appropriate backbone regimen to manage a patient with relapsed or refractory multiple myeloma.

Healthcare stakeholders comment on current practices managing patients with relapsed/refractory multiple myeloma during the COVID pandemic and discuss their comfort switching patients over from intravenous daratumumab to subcutaneous daratumumab.

Factors that influence treatment selection for relapsed or refractory multiple myeloma, and suggestions to help streamline decision making and address limitations associated with current treatment pathways.

A historical review of treatment advances in relapsed/refractory multiple myeloma and criteria used to define relapsed or refractory disease.

The FDA has granted a fast track designation to poziotinib for use in previously treated non-small cell lung cancer patients with HER2 exon 20 mutations.

With schools around the nation reopening, it is time to think about managing diabetes in the classroom.

Danielle DiBari, the chief pharmacy officer and senior vice president of business operations for NYC Health + Hospitals, discusses some of the challenges involved in coordinating vaccine distribution across New York’s public health system.

The receipt of preventive care for youth enrolled in Medicaid managed care fell significantly short of the annual goal set by the Centers for Medicare and Medicaid Services (CMS).

The oral, next-generation vascular endothelial growth factor tyrosine kinase inhibitor is the first therapy approved for this patient population following 2 or more prior systemic therapies.

An ongoing phase 2 clinical study has begun to vaccinate patients with a modified version of Moderna’s COVID-19 vaccine.

A recent research review found that a large proportion of COVID-19 survivors will be affected by neuropsychiatric and cognitive complications.

Study finds cancer survivors were 42% more likely to report walking at the slowest pace and had a 24% greater risk of mobility disability compared to individuals who never had cancer.

The change in guidelines address how to assess damage to the kidneys caused by fluid loss associated with severe C. diff infection.

A recent survey showed that there is a significant preference among Americans to receive COVID-19 vaccines from a trusted health care provider, such as a pharmacist or physician.

The Covid-19 pandemic has elevated telehealth as a viable alternative to face-to-face interactions under certain circumstances, the list of which is expanding as technology expands and clinicians become more accustomed to and adept in its use.

Dwight Kloth, PharmD, FCCP, BCOP, director of pharmacy at Fox Chase Cancer Center, discusses the role of the oncology pharmacist in the cancer care continuum, and how this role has been impacted by the COVID-19 pandemic.

Chad Landmon, JD, chair of intellectual property and FDA practice groups at Axinn, Veltrop & Harkrider, discusses how the COVID-19 pandemic has impacted the FDA’s approval process.

The potential for some people to skip the second COVID-19 vaccine dose may make more doses available to others.

Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, discuss the management of stomatitis caused by everolimus when used for NETs.

Cecilia Lau, RPh, BCOP, APh, reviews the efficacy and safety data for everolimus in the treatment of NETs.

Megan May, PharmD, BCOP, and Daneng Li, MD, discuss the availability of home-injection programs for patients with NETs, especially during the coronavirus pandemic.

Experts in the management of NETs review the various delivery systems and preparations available for short- and long-acting somatostatin analogues.

Megan May, PharmD, BCOP, and Cecilia Lau, RPh, BCOP, APh, discuss the pharmacists’ role in choosing the treatment plan for patients with NETs.

The panel of experts discuss how they choose 1 somatostatin analogue over another and the factors to consider in the management of NETs.

Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, review the differences among the somatostatin analogues, particularly the differences in PK data.

The panel of experts in the management of NETs review the indications and safety data of the somatostatin analogues.

Megan May, PharmD, BCOP, and Daneng Li, MD, review the efficacy and the pivotal trials for the somatostatin analogues in the treatment of NETs.